

Călătoriile germanilor multirezistenți


Cristian-Mihail Niculae

UMF *Carol Davila*, București


INBI *Prof. Dr. Matei Balș*, București

"Pandemia silentioasă" de rezistență la antibiotice

- 2019 - 1.27 mil. DECESE cauzate de bacterii REZISTENTE la antimicrobiene;¹




Deaths attributable to AMR every year compared to other major causes of death




- comparativ, pandemia Covid-19 (mai 2022) - aprox. 527 mil. cazuri - 6.28 mil. DECESE;

¹Murray, C. L. J. et al. *Lancet* 2022;


Rezistență *Klebsiella pneumoniae* la carbapeneme (EARS Net, 2019)




Rezistență *Pseudomonas aeruginosa* la carbapeneme (EARS Net, 2019)




Rezistență *Acinetobacter* la carbapeneme (EARS Net, 2019)




MRSA în statele membre ale UE/EEA (EARS-Net 2019)



Utilizarea de antibiotice animale/oameni



Antibiotic use in animals & humans



Animal reservoir of antibiotic resistance



Human reservoir of antibiotic resistance

- Human use (general practice and hospitals)
- Animal therapeutic use
- Animals (as feed additive antibiotics)

Antibiotic overuse is breeding new, resistant strains of bacteria that infect people. But industrial farms haven't gotten the message.

In 2011, 29.9 million pounds of antibiotics were sold in the United States for meat and poultry production.

3.9 times greater

Yet, in the same period, only 7.7 million pounds of antibiotics were sold to treat sick people in the United States.



Food-producing animals develop drug-resistant bacteria in their gut when antimicrobial substances are used for therapy and/or prophylaxis of bacterial infections in them or with antimicrobial substances' administration in animal feeds as growth promoters



Human beings get antibiotics and develop drug-resistant bacteria in their gut.



Fertilizer including drug-resistant bacteria can be used on food crops




Drug-resistant bacteria remain on meat of these animals and/or on food crops that manure or sewage water is used for fertilization and irrigation, and they can be eaten by human beings




Human beings directly spread drug-resistant bacteria to other people in the public or to vulnerable patients at the hospital or drug-resistant bacteria indirectly spread to other patients from surfaces within the hospital

Antimicrobials use and resistance



Resistant bacteria survive,
those susceptible most
likely die.



“Natural Selection”

Antimicrobial Resistance in G7 Countries and Beyond; Albrich et al 2004

Failure of MDRO prevention and control

- sources for MDRO outside healthcare facilities
- density of healthcare-usage & healthcare facilities
- transfer of patients between healthcare institutions
- lack of outbreak control
- delayed begin of bundle implementation
- wrong or incompletely implemented MDRO prevention bundles
- lack of isolation capacity
- lack of diagnostics, typing & screening
- lack of financial ressources
- too low healthcare staffing levels
- non-prudent use of antibiotics
- lack of education
- lack of compliance with hand hygiene

Tourists on holiday “pick up” antibiotic resistant genes


Related Stories

Back from vacation? Your gut bacteria picked up souvenirs, too

Meredith Knight | July 31, 2016 | Genetic Literacy Project

The dreaded [traveler's diarrhea](#) is the most common illness associated with vacationing or working abroad.

It's so common the [CDC](#) estimates 30 to 70 percent of travelers are affected, depending on where they go. Most cases are caused from food or water contaminated with locale-specific bacteria. Those bacteria cause the adverse reaction in our guts. They can also carry antibiotic resistance genes. And it turns out we can pick up those bugs very quickly—just 48 hours according to new research presented at the [American Society for Microbiology](#) meeting.




CDC: 30 to 70 percent of travelers are affected, depending on where they go.

**Back from vacation?
Your gut bacteria picked up souvenirs, too**



Genes picked up by the bacteria in the traveler's guts depended on **where** they went on vacation

Proportion of travelers who acquired MDR Enterobacteria by travel destination




South and Central America (0–33%)

North America, Europe and Oceania was rare.


Hassing et al Eurosurveillance 2015

World map indicating the risk levels of contracting extended-spectrum beta-lactamase-producing Enterobacteriaceae



How long does the carriage last?

Survival curve representing multidrug-resistant *Enterobacteriaceae* (MRE) carriage rates among travelers during follow-up, according to the travel destination



High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics


MDR/ESBL colonization: three levels of significance



MDR/ESBL colonization: Individual level

- Usually asymptomatic
- Risk of infection:
 - generally low (1%?)
 - higher (10%?)
 - the longer the colonization lasts
 - for severely ill
 - for hospitalized patients, particularly if antibiotics/intensive care
- Infections:
 - urinary tract infections → life threatening septicemia
 - more difficult to treat
 - increased mortality

MDR/ESBL colonization: three levels of significance



The globalisation of AMR

- Infected by a resistant pathogen
 - may make treatment more difficult (if warranted)
- Colonised by a resistant pathogen
 - may cause infection at future date
 - may pass its genes to susceptible flora
- Transient passage of a resistant pathogen
 - may pass its genes to susceptible flora

Who are the enemies?

Running out of artillery:
the fight against CREs and other resistant Gram-negative bacteria

| Pathogen | Established problems | Emerging threats |
|----------------------|----------------------|-------------------------|
| <i>E. faecium</i> | VRE, HLGR, Amp-R | Lin-R, Dap-R, Tig-R |
| <i>S. aureus</i> | MRSA (ha/ca) | Van-R, Lin-R, Dap-R |
| <i>Klebsiella</i> | ESBLs | Carbapenemases, Col-R |
| <i>Acinetobacter</i> | MDR, Carbapenemases | Tig-R, Col-R |
| <i>Pseudomonas</i> | MDR, except Col | Carbapenemases, Col-R |
| <i>Enterobacter</i> | AmpC, ESBLs | Carba-R, Carbapenemases |
| <i>E. coli</i> | Cip-R, ESBLs | Carbapenemases |

Antibiograma - Metoda difuzimetrica

Denumire organism **Klebsiella pneumoniae**
 Betalactamaza
 ESBL
 Carbapenemaza
 MBL
 Rezistenta inductibila Clindamicina

| Antibiotic | Valoare | UM | Caracteristica |
|-------------|---------|----|----------------|
| Cefiderocol | 6 | mm | R |

Antibiograma - Metoda CMI

Denumire organism **Klebsiella pneumoniae**
 Betalactamaza
 ESBL **Pozitiv**
 Carbapenemaza
 MBL **Pozitiv**
 Rezistenta inductibila Clindamicina

| Antibiotic | Valoare | UM | Caracteristica |
|------------------------|---------|-------|----------------|
| Amikacin | >16 | µg/ml | R |
| Ampicillin/Sulbactam | >8/4 | µg/ml | R |
| Ceftazidime/Avibactam | >8/4 | µg/ml | R |
| Ceftazidim | >32 | µg/ml | R |
| Ciprofloxacin | >1 | µg/ml | R |
| Colistin | >4 | µg/ml | R |
| Cefoxitin | >8 | µg/ml | R |
| Ceftriaxon | >2 | µg/ml | R |
| Ceftolozane/Tazobactam | >4/4 | µg/ml | R |
| Ertapenem | >0.5 | µg/ml | R |
| Gentamicin | >4 | µg/ml | R |
| Imipenem | >4 | µg/ml | R |
| Levofloxacina | >4 | µg/ml | R |

| | | | |
|------------------------------|-------|-------|---|
| Meropenem | >32 | µg/ml | R |
| Piperacillin/Tazobactam | >16/4 | µg/ml | R |
| Trimethoprim/Sulfamethoxazol | >4/76 | µg/ml | R |
| Tigecicline | =1 | µg/ml | |
| Aztreonam | >16 | µg/ml | R |
| Fosfomycin | >32 | µg/ml | R |

Greșeli frecvente de prescriere a antibioticelor

- 1. LIPSA DIAGNOSTICULUI CLINIC**
- 2. LIPSA DIAGNOSTICULUI BACTERIOLOGIC**
- 3. INDICAȚII NEJUSTIFICATE**
- 4. ALEGAREA GREȘITĂ A ANTIBIOTICELOR**
- 5. GREȘELI ÎN SCHEMA TERAPEUTICĂ**
- 6. ABUZ IN PROFILAXIA CU ANTIBIOTICE**
- 7. PRESCRIEREA "DEFENSIVĂ" DE ANTIBIOTICE**

COLONIZARE sau INFECȚIE?

COLONIZARE

- **Toleranța** organismului față de prezența bacteriilor;
- **Pacientul este ASIMPTOMATIC;**
- De regulă, **tratamentul antibiotic NU este necesar;**
- **Colonizarea este NORMALĂ***;
- **Orice corp străin** prezent în organism și care are legătură cu mediul exterior **se poate coloniza (CVC, sonde urinare, drenaje externe) sau ulcere, etc.**
- **Germenii SENSIBILI sau multi-REZISTENȚI;**


INFECȚIE

- **Absența toleranței** organismului față de prezența bacteriilor (conflict imun);
- **Pacientul este SIMPTOMATIC;**
- De regulă, este **necesar un tratament antibiotic;**
- **Germenii SENSIBILI sau multi-REZISTENȚI;**

The Power of Bacteria

Age:

| | |
|------------------|---------------------|
| Bacteria | 3,500,000,000 years |
| Eukaryotes | 1,800,000,000 years |
| Multicellulars | 580,000,000 years |
| Australopithecus | 4,000,000 years |
| Homo erectus | <2,000,000 years |
| Antibiotic use | 60 years |



Numbers:

“The number of *E.coli* in the gut of each human being far exceed the number of people that now live or have ever inhabited the earth” !!!

They are ubiquitous and indestructible

Colonizare sau infecție?

Exemplul 2 - La nivelul tractului urinar

- pacient asimptomatic, urocultură pozitivă (**corect recoltată și prelucrată < 2h de la recoltare - de verificat întotdeauna!**);

| Bacteriologie | |
|-----------------------------------|----------------|
| Analiza : UROCULTURA | |
| PESTE 100.000 UFC/ml | |
| Analiza : IDENTIFICARE BACTERIANA | |
| Klebsiella spp | |
| Analiza : ANTIBIOGRAMA | |
| Antibiotic | Caracteristica |
| Fosfomicin | Sensibil |
| Ertapenem | Rezistent |
| Ceftazidim | Rezistent |
| Amoxicilina-acid clavulanic | Rezistent |
| Cefuroxim | Rezistent |
| Gentamicina | Rezistent |
| Norfloxacin | Rezistent |
| Co-trimoxazol | Rezistent |
| Nitrofurantion | Rezistent |

Colonizare sau infecție?

Exemplu clinic - La nivelul tractului urinar

Colonizare = BACTERIURIE ASIMPTOMATICĂ (BA) - diagnostic

- Urocultură semnificativă
 - ♀: **2 uroculturi** (aceeași tulpină) cu $\geq 10^5$ UFC/mL
 - ♂: **1 urocultură** (corect recoltată) cu $\geq 10^5$ UFC/mL
- **FĂRĂ SIMPTOME/SEMNE DE INFECȚIE** (! Aspectul și/sau mirosul modificat nu fac parte din tabloul clinic, fără alte simptome asociate)

Colonizare sau infecție?

Exemplu clinic - La nivelul tractului urinar

NU li se vor recolta **UROCULTURI** pacienților **ASIMPTOMATICI***, chiar dacă/cu atât mai mult cu cât **ȘI NU SE TRATEAZĂ**:

- **Vârstnici/instituționalizați;**
- **Diabet zaharat**, alte comorbidități;
- Pacienți cu patologie medulară;
- **Pacienți purtători de sondă urinară;**

Excepții *:

1. **GRAVIDE** (testare trimestrial);
2. **PROCEDURI UROLOGICE INVAZIVE** (NU montare/schimbare **sondă vezicală!**) - mai ales **TURP**, schimbare **sondă ureterală**;

Colonizare sau infecție?

Exemplu clinic - La nivelul tractului urinar

NU se TRATEAZĂ:

- **Bacteriuria asimptomatică;**
- **Modificările din sumarul de urină + bacteriuria asimptomatică;**

Excepții:

1. **GRAVIDE** - testare trimestrial, **tratament 3-7 zile** (ex: *E.coli* sensibil – **amoxi-clavulanat**),
ulterior urocultură lunar, până la naștere;
2. **PROCEDURI UROLOGICE INVAZIVE** (NU la înlocuire/montare sondă vezicală!) – mai
ales **TURP**, schimbare **sondă ureterală**;

What then ?

These data all give the same impression: R bacteria is like climate change: everyone is aware of the problem, we know that the disaster is possible but as the solutions are not obvious we do nothing, or not so much.



Vă mulțumesc!

